Company* |
Funding |
Amount |
Type# |
Details (Date) |
Active Pass |
National Institute |
C$3.6 | Grant |
The award will support development of a treatment for secretory diarrhea (10/1) |
Adenosine |
National Institutes | $1.25 |
Phase II SBIR grant | The grant will fund research with the University of Virginia to test the combination of two anti-inflammatory drugs, ATL146e and a Type IV PDE inhibitor, in a drug-eluting stent (12/6) |
Affymetrix |
National Institute | $2.1 |
Grant |
To develop a biodefense microarray test that can detect hundreds of bacterial and viral biological threats (10/19) |
Althea |
National Cancer | ND |
Phase I SBIR grant | To establish validated, quantitative gene expression assays that serve as "genetic signatures" for diagnosing multiple pediatric cancers (10/19) |
Amyris |
Bill and Melinda | $12 |
Grant |
Amyris will get $12M of a $42.6M grant that is funding work on an affordable drug for malaria; also working on the project are One-World Health and the University of California at Berkeley (12/13) |
Attenuon |
National Cancer | $0.358 |
Phase I/II STTR grant | To evaluate derivatives of the peptide ATN-161 as agents for PET imaging; another $942,000 could be awarded for years two and three if milestones are met (10/28) |
BioLineRx |
Israeli Office of | $21 |
Grant |
The company said it was the sole recipient of a grant for development of preclinical compounds as part of an initiative to advance the industry in Israel (12/2) |
Biolog Inc.* |
National Institutes | ND |
STTR grant |
To collaborate with Johns Hopkins University to develop Biolog's Phenotype MicroArray technology to study gene function in Saccharomyces cerevisiae (10/25) |
Biolog Inc.* |
National Institutes | ND |
STTR grant |
To collaborate with Washington University to develop Biolog's Phenotype MicroArray technology for use with fastidious pathogens (10/21) |
Biolog Inc.* |
National Institutes | $2.5 |
Phase II SBIR grant | To further develop a cell-based assay as an in vitro replacement to animal models in some toxicology testing applications (10/13) |
Bionomics |
Federal government | A$0.247 (US$0.19) |
Biotechnology Innovation Fund grant | To support work on developing targets for antibody treatments which inhibit blood vessel formation (angiogenesis) in cancer and other diseases (11/4) |
Biophage |
Canadian | ND |
Financial support | To help open the Brazilian market to Biophage's therapeutic and diagnostic products (10/15) |
Biota |
National Institute | $5.6 |
Grant |
For development of a new influenza drug as part of the NIH's pandemic preparedness strategy (9/30)# |
BioTie |
The National | €3.3 (US$4.5) |
R&D support | The loan and subsidy will support development of the VAP-1 SSAO small-molecule inhibitor program from August 2004 to July 2006 (11/17) |
Bioxel Pharma |
Investissement Quebec Immigrant Investors | C$0.5 (US$0.4) |
Financial contribution |
Bioxel will get the money in four annual installments as part of a program to help businesses (10/7) |
Cambridge |
Department for International Development (UK) | £0.950 (US$1.76) |
Grant |
To apply its glass-stabilizing technology to develop a pentavalent vaccine in a temperature-stable liquid form for use in developing countries (10/21) |
Cangene |
Centers for Disease Control and Prevention | ND |
Contract award |
The CDC intends to negotiate a sole-source agreement for Cangene to provide up to 200,000 doses of botulinum toxin immune globulin (10/18) |
Carrington |
National Institute | $6 |
Grant |
Three-year grant will fund work on an inactivated influenza nasal powder vaccine against the H5N1 strain, using its GelVac delivery system (10/5) |
Cellartis AB* |
National Institutes | ND |
Infrastructure award |
The NIH granted a second year of funding for further work on human embryonic stem cell lines derived before Aug. 9, 2001 (10/19) |
Cortical Pty. |
Federal government of Australia | A$2.5 (US$1.93) |
R&D Start | The funds will support development of small-molecule macrophage migration inhibitory factors for inflammatory diseases (11/5) |
CytImmune |
National Institute | $2 |
Advanced Technology Program award |
For development of a semi-synthetic human immune system on colloidal gold nanoparticles, for production of fully human monoclonal antibodies (11/18) |
DeCode |
National Institute | $23.9 |
Contract available to researchers (10/8) |
DeCode will apply its population approach to discover genetic factors associated with susceptibility to certain infectious diseases and with vaccine response; the National Center for Genome Resources will provide bioinformatics resources to make results |
Elusys |
National Institute | $5.5 and $3 |
Funding support and grant | To support development and research for Anthim (ETI-204), an antibody treatment for exposure to anthrax toxin (10/13) |
Endocyte |
National Cancer Institute and the Indiana 21st Century Research and Technology Fund | $3.58 |
Grants |
The NCI grant of $1.63M and the state grant of $1.95M will be used for preclinical tests using folate to transform cancer drugs into tumor-targeted agents (11/15) |
EpiVax Inc.* |
National Institutes | $0.994 |
BioDefense | The grant provides EpiVax with funds to develop a genome-derived, epitope-driven smallpox vaccine (12/20) |
ES Cell |
National Institutes | ND |
Grant |
Three-year grant will support human embryonic stem cell research (10/14) |
454 Life |
National Human Genome Research Institute | $5 |
Grant |
Three-year grant will support development of the company's technology as a method to routinely sequence individual human genomes on PicoTiter-Plates (10/14) |
Gene Logic |
National Institute | $6 |
Agreement |
Gene Logic could get $6M over four years to provide preclinical safety and pharmacology studies focused on treating drug addiction (10/8) |
GenoMed |
National Institute | ND |
Contract |
For further testing of GenoMed's approach against viral diseases, including influenza (10/20) |
Hawaii |
National Institute | $9.9 |
BioShield | A $6.3M grant and a $3.3M grant will support preclinical and Phase I development of a vaccine for dengue virus (12/10) |
Hawaii Biotech Inc.* |
National Institute | $5.9 |
Phase II SBIR grant | The grant will fund preclinical development of a West Nile virus vaccine (12/10) |
Iconix |
National Cancer | ND |
Phase I SBIR grant | The grant will support development of an in vitro system to detect specific forms of liver pathology (12/21) |
ID Biomedical |
National Institutes | $5.6 |
Grant |
The grant of up to $5.6M will support development of a nasally administered subunit vaccine to protect against severe acute respiratory syndrome (10/1) |
Isis Pharma- |
Various U.S. government agencies | $10 |
Contract | Three contracts valued at up to $10M will fund continued development of various applications of its TIGER biosensor technology (10/7) |
Jerini AG* |
German Federal | €0.847 (US$1.1) |
Funding | The money will support discovery and preclinical development of an orally available bradykinin B2 receptor antagonist (12/8) |
KBI |
National Science Foundation | $0.5 |
Phase II SBIR grant | To support the application of KBI's Centrifugal Bioreactor technology to biopharmaceutical production (10/20) |
Kereos Inc.* |
National Heart, | $7.3 |
Biomedical Research Partnership grant | The university's grant will support their work in developing ligand-targeted products for treating unstable plaque (11/18) |
LAB |
The National Technology Agency of Finland | C$4.6 (US$3.9) |
R&D support | Finish subsidiary LAB Pharma will use the funds on its inhaled fentanyl formulation and for inhaled protein products (11/29) |
Lynx |
National Science Foundation | ND |
Research grant |
The University of Delaware will use the grant to develop methods to capture and sequence small RNAs on a larger scale, using Lynx's MPSS technology (10/19) |
Medarex |
National Institute | $7.6 |
Grants |
Two milestone-driven grants over three years will support development of MDX-1303, a fully human antibody for anthrax infection (10/4) |
Meridian |
National Institutes | ND |
Phase I SBIR grant | To develop specific recombinant antibodies to Clostridium difficile toxins A & B, and then use the antibodies to develop diagnostics (10/5) |
Microchip |
National Human Genome Research Institute | $6.1 |
Grant |
To develop a nanofluidic technological platform that would reduce the cost of DNA sequencing (11/10) |
Mirus Bio |
National Institutes | $1.26 |
Phase II SBIR grant | To develop a gene-therapy product to treat anemia using its Pathway IV gene-delivery plat- form (10/6) |
Mologen |
Innovation Support Program of Berlin | €0.212 (US$0.26) |
Funding subsidy | The money will be used for final preclinical development of a cell-based, tumor-specific product for kidney cancer (10/5) |
Newron |
European | €1.83 (US$2.5) |
Cooperative Research Programme funding | Newron will lead a consortium to develop a high-throughput system for screening molecules that act on ion channel targets related to neurological diseases (12/1) |
Novasite |
National Institutes | $3.365 |
Bioengineering grant | The grant supports scale-up of Single Cell Screening technology for parallel screening of more than 100 G protein-coupled receptors (11/16) |
Onyvax |
European | €1.6 (US$2.1) |
Sixth Framework Program grant | Onyvax, Mubio Products BV, Cires GmbH, Medical Proteom-Center and the University of Maastricht make up the consortium that received the funds to develop vaccine therapies for lung cancer (10/29) |
Perlegen |
National Institute | $13.2 |
Contract award | To identify sequence variation in inbred mouse strains; it will use Affymetrix Inc. technology in the work (10/26) |
Potomac |
Stanley Medical Research Center | $2.2 |
Funding support | To support development of P-101, Potomac's Phase II alpha-2 antagonist being developed for schizophrenia (10/19) |
Progenics |
National Cancer | $7.4 |
Phase II SBIR grants | One grant will fund development of a fully human, PSMA-targeting monoclonal antibody for meta- static prostate cancer; the second will support development of a recombinant soluble PSMA vaccine (11/2) |
Protalix |
Governments | ND |
BIO-DISC grant |
The funding will support their collaboration to develop genetic constructs as the basis for a platform for ultra-high-level expression of recombinant proteins in plant cells (11/12) |
RiboNovix |
National Institutes | $0.346 |
Phase I SBIR grant | For research to construct a functional E. coli rRNA mutation library and identify new anti-infective rRNA targets in E. coli (10/5) |
RxGen Inc.* |
National Institutes | $1.1 |
Fast-track SBIR grant | The company will use its genomics and bioinformatics technologies to discover genomic markers of Parkinson's disease (12/7) |
RxGen Inc.* |
National Institutes | $1.4 |
Phase I and II SBIR grants | To support development of PrimaTox as a platform to predict human toxic response to new pharmaceutical compounds (10/5) |
Samaritan |
National Institutes | $0.1 |
STTR grant |
The company and Georgetown University will use the grant to research SP-004, their Alzheimer's disease agent (10/19) |
Stellar Bio- |
National Cancer | $3 |
Phase II SBIR grant | Extension of the grant will fund development of technologies for its Keyhole Limpet Hemocyanin cancer vaccine program (10/4) |
VaxGen Inc. |
U.S. government | $877.5 |
Contract |
The contract under Project Bio- Shield calls for VaxGen to supply 75M doses of its recombinant Protective Antigen anthrax vaccine within three years for use in civilian defense (11/4) |
VaxInnate |
Department of | ND |
Grant |
The grant will be used to discover Toll-like receptor ligands with adjuvant properties (10/11) |
VaxInnate |
Department of | ND |
Contract |
To use its approach to discover and optimize Toll-like receptor ligands for use in vaccines against infectious diseases (10/11) |
Notes: | ||||
* Indicates a privately held company. | ||||
Currency conversions reflect values at the time of a deal's announcement. | ||||
SBIR = Small Business Innovation Research; STTR = Small Business Technology Transfer. | ||||
# Item occured before the time frame on this chart but was not included in the previous chart. | ||||
Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; HEX = Helsinki Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | ||||
